Annual report pursuant to Section 13 and 15(d)

Segments

v2.4.1.9
Segments
12 Months Ended
Dec. 31, 2014
Segment Reporting [Abstract]  
Segments
Segments
We currently manage our operations in two reportable segments, pharmaceuticals and diagnostics. The pharmaceuticals segment consists of two operating segments, our (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products, and vaccines, and (ii) the pharmaceutical operations we acquired in Chile, Mexico, Israel, Spain, Brazil, and Uruguay. The diagnostics segment consists of two operating segments, our (i) pathology operations we acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. There are no inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the years ended December 31,
(In thousands)
2014
 
2013
 
2012
Product revenues:
 
 
 
 
 
Pharmaceuticals
$
76,983

 
$
68,161

 
$
45,295

Diagnostics

 

 

Corporate

 

 

 
$
76,983

 
$
68,161

 
$
45,295

Revenue from services:
 
 
 
 
 
Pharmaceuticals
$

 
$

 
$

Diagnostics
8,426

 
10,833

 
395

Corporate
240

 
825

 
1,354

 
$
8,666

 
$
11,658

 
$
1,749

Revenue from transfer of intellectual property:
 
 
 
 
 
Pharmaceuticals
$
5,285

 
$
15,160

 
$

Diagnostics
191

 
1,551

 

Corporate

 

 

 
$
5,476

 
$
16,711

 
$

Operating (loss) income:
 
 
 
 
 
Pharmaceuticals
$
(94,401
)
 
$
(29,809
)
 
$
(6,797
)
Diagnostics
(21,647
)
 
(22,199
)
 
(14,259
)
Corporate
(27,725
)
 
(24,473
)
 
(15,628
)
Less: Operating loss attributable to noncontrolling interests
(2,042
)
 
(3,151
)
 
(585
)
 
$
(145,815
)
 
$
(79,632
)
 
$
(37,269
)
Depreciation and amortization:
 
 
 
 
 
Pharmaceuticals
$
7,936

 
$
8,234

 
$
6,367

Diagnostics
6,894

 
6,833

 
3,614

Corporate
97

 
149

 
179

 
$
14,927

 
$
15,216

 
$
10,160

Net loss from investment in investees:
 
 
 
 
 
Pharmaceuticals
$
(3,587
)
 
$
(11,456
)
 
$
(2,062
)
Diagnostics

 

 

Corporate

 

 

 
$
(3,587
)
 
$
(11,456
)
 
$
(2,062
)
Revenues:
 
 
 
 
 
United States
$
14,142

 
$
28,369

 
$
1,749

Chile
29,154

 
31,650

 
26,514

Spain
21,323

 
18,800

 
6,124

Israel
20,638

 
13,252

 
7,655

Mexico
5,807

 
4,459

 
5,002

Other
61



 

 
$
91,125

 
$
96,530

 
$
47,044


(In thousands)
December 31,
2014
 
December 31,
2013
Assets:
 
 
 
Pharmaceuticals
$
1,064,498

 
$
1,065,033

Diagnostics
108,072

 
116,944

Corporate
95,094

 
209,539

 
$
1,267,664

 
$
1,391,516

Goodwill:
 
 
 
Pharmaceuticals
$
173,327

 
$
175,408

Diagnostics
50,965

 
50,965

Corporate

 

 
$
224,292

 
$
226,373


During the year ended December 31, 2014, one customer of our pharmaceutical segment represented 13% of our total revenue. During the years ended December 31, 2013, and 2012, no customer represented more than 10% of our total revenue. As of December 31, 2014, 2013, and 2012, no customer represented more than 10% of our accounts receivable balance.